Psychemedics Corporation (PMD)
USD 2.67
(0.0%)
USD 2.67
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 11.33 Million USD | 9.25% |
| 2022 | 10.37 Million USD | 3.17% |
| 2021 | 10.05 Million USD | -8.19% |
| 2020 | 10.95 Million USD | -18.55% |
| 2019 | 13.44 Million USD | 3.37% |
| 2018 | 13 Million USD | 11.51% |
| 2017 | 11.66 Million USD | 2.87% |
| 2016 | 11.34 Million USD | 0.84% |
| 2015 | 11.24 Million USD | 7.63% |
| 2014 | 10.44 Million USD | 7.85% |
| 2013 | 9.68 Million USD | 3.99% |
| 2012 | 9.31 Million USD | 7.42% |
| 2011 | 8.67 Million USD | 13.7% |
| 2010 | 7.62 Million USD | 8.56% |
| 2009 | 7.02 Million USD | -18.72% |
| 2008 | 8.64 Million USD | 14.67% |
| 2007 | 7.53 Million USD | 16.09% |
| 2006 | 6.49 Million USD | 3.88% |
| 2005 | 6.25 Million USD | 2.18% |
| 2004 | 6.11 Million USD | -4.9% |
| 2003 | 6.43 Million USD | -9.58% |
| 2002 | 7.11 Million USD | -6.3% |
| 2001 | 7.59 Million USD | -3.84% |
| 2000 | 7.89 Million USD | -11.29% |
| 1999 | 8.9 Million USD | 12.66% |
| 1998 | 7.9 Million USD | 12.86% |
| 1997 | 7 Million USD | 32.08% |
| 1996 | 5.3 Million USD | 12.77% |
| 1995 | 4.7 Million USD | 30.56% |
| 1994 | 3.6 Million USD | 12.5% |
| 1993 | 3.2 Million USD | 10.34% |
| 1992 | 2.9 Million USD | 16.0% |
| 1991 | 2.5 Million USD | -10.71% |
| 1990 | 2.8 Million USD | 2700.0% |
| 1989 | 100 Thousand USD | -94.44% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.68 Million USD | -8.1% |
| 2024 Q2 | 2.45 Million USD | -8.85% |
| 2023 Q4 | 2.92 Million USD | -8.51% |
| 2023 Q2 | 2.47 Million USD | -9.4% |
| 2023 Q1 | 2.73 Million USD | 5.07% |
| 2023 Q3 | 3.19 Million USD | 29.16% |
| 2023 FY | 11.33 Million USD | 9.25% |
| 2022 Q3 | 2.7 Million USD | 3.52% |
| 2022 Q1 | 2.45 Million USD | -22.19% |
| 2022 Q2 | 2.61 Million USD | 6.69% |
| 2022 Q4 | 2.6 Million USD | -3.92% |
| 2022 FY | 10.37 Million USD | 3.17% |
| 2021 Q4 | 3.15 Million USD | 41.57% |
| 2021 Q2 | 2.22 Million USD | -9.06% |
| 2021 Q3 | 2.22 Million USD | -0.18% |
| 2021 FY | 10.05 Million USD | -8.19% |
| 2021 Q1 | 2.45 Million USD | 2.72% |
| 2020 FY | 10.95 Million USD | -18.55% |
| 2020 Q4 | 2.38 Million USD | -6.14% |
| 2020 Q3 | 2.54 Million USD | -16.76% |
| 2020 Q2 | 3.05 Million USD | 2.83% |
| 2020 Q1 | 2.97 Million USD | -27.4% |
| 2019 FY | 13.44 Million USD | 3.37% |
| 2019 Q2 | 2.84 Million USD | -17.93% |
| 2019 Q3 | 3.04 Million USD | 7.21% |
| 2019 Q4 | 4.09 Million USD | 34.22% |
| 2019 Q1 | 3.46 Million USD | 8.08% |
| 2018 FY | 13 Million USD | 11.51% |
| 2018 Q2 | 3.11 Million USD | -9.65% |
| 2018 Q1 | 3.44 Million USD | 21.87% |
| 2018 Q3 | 3.23 Million USD | 3.92% |
| 2018 Q4 | 3.2 Million USD | -1.02% |
| 2017 FY | 11.66 Million USD | 2.87% |
| 2017 Q4 | 2.83 Million USD | -2.04% |
| 2017 Q1 | 3.04 Million USD | 10.39% |
| 2017 Q2 | 2.89 Million USD | -4.89% |
| 2017 Q3 | 2.88 Million USD | -0.34% |
| 2016 Q4 | 2.76 Million USD | -7.99% |
| 2016 FY | 11.34 Million USD | 0.84% |
| 2016 Q3 | 3 Million USD | 5.74% |
| 2016 Q2 | 2.83 Million USD | 3.57% |
| 2016 Q1 | 2.74 Million USD | 7.97% |
| 2015 Q2 | 2.91 Million USD | 0.88% |
| 2015 Q1 | 2.88 Million USD | 14.44% |
| 2015 FY | 11.24 Million USD | 7.63% |
| 2015 Q3 | 2.9 Million USD | -0.28% |
| 2015 Q4 | 2.53 Million USD | -12.65% |
| 2014 FY | 10.44 Million USD | 7.85% |
| 2014 Q1 | 2.62 Million USD | 0.35% |
| 2014 Q3 | 2.72 Million USD | 5.98% |
| 2014 Q4 | 2.52 Million USD | -7.39% |
| 2014 Q2 | 2.57 Million USD | -2.14% |
| 2013 Q4 | 2.61 Million USD | 7.46% |
| 2013 Q1 | 2.28 Million USD | -0.72% |
| 2013 Q3 | 2.43 Million USD | 3.81% |
| 2013 Q2 | 2.34 Million USD | 2.72% |
| 2013 FY | 9.68 Million USD | 3.99% |
| 2012 Q3 | 2.28 Million USD | -6.25% |
| 2012 Q2 | 2.43 Million USD | 6.6% |
| 2012 Q1 | 2.28 Million USD | -5.77% |
| 2012 FY | 9.31 Million USD | 7.42% |
| 2012 Q4 | 2.3 Million USD | 0.65% |
| 2011 Q3 | 2.13 Million USD | 7.87% |
| 2011 Q4 | 2.42 Million USD | 13.67% |
| 2011 Q1 | 2.12 Million USD | -11.55% |
| 2011 FY | 8.67 Million USD | 13.7% |
| 2011 Q2 | 1.98 Million USD | -6.87% |
| 2010 Q1 | 1.71 Million USD | 9.98% |
| 2010 Q4 | 2.4 Million USD | 42.3% |
| 2010 Q3 | 1.68 Million USD | -6.93% |
| 2010 FY | 7.62 Million USD | 8.56% |
| 2010 Q2 | 1.81 Million USD | 5.69% |
| 2009 FY | 7.02 Million USD | -18.72% |
| 2009 Q4 | 1.56 Million USD | -3.42% |
| 2009 Q3 | 1.61 Million USD | -10.55% |
| 2009 Q2 | 1.8 Million USD | -11.34% |
| 2009 Q1 | 2.03 Million USD | -11.47% |
| 2008 Q4 | 2.3 Million USD | 0.83% |
| 2008 Q2 | 2.11 Million USD | 9.18% |
| 2008 Q1 | 1.93 Million USD | 1.34% |
| 2008 FY | 8.64 Million USD | 14.67% |
| 2008 Q3 | 2.28 Million USD | 7.89% |
| 2007 Q1 | 1.63 Million USD | 2.09% |
| 2007 Q2 | 1.99 Million USD | 22.34% |
| 2007 Q3 | 1.99 Million USD | -0.05% |
| 2007 Q4 | 1.91 Million USD | -4.12% |
| 2007 FY | 7.53 Million USD | 16.09% |
| 2006 Q1 | 1.54 Million USD | 2.01% |
| 2006 Q4 | 1.59 Million USD | -4.13% |
| 2006 FY | 6.49 Million USD | 3.88% |
| 2006 Q3 | 1.66 Million USD | -1.0% |
| 2006 Q2 | 1.68 Million USD | 9.22% |
| 2005 Q3 | 1.55 Million USD | 3.22% |
| 2005 FY | 6.25 Million USD | 2.18% |
| 2005 Q4 | 1.51 Million USD | -2.88% |
| 2005 Q2 | 1.5 Million USD | -9.9% |
| 2005 Q1 | 1.67 Million USD | 6.47% |
| 2004 Q4 | 1.57 Million USD | 0.67% |
| 2004 FY | 6.11 Million USD | -4.9% |
| 2004 Q3 | 1.56 Million USD | 0.35% |
| 2004 Q2 | 1.55 Million USD | 9.01% |
| 2004 Q1 | 1.42 Million USD | 33.84% |
| 2003 Q4 | 1.06 Million USD | -41.36% |
| 2003 FY | 6.43 Million USD | -9.58% |
| 2003 Q3 | 1.81 Million USD | -0.31% |
| 2003 Q1 | 1.72 Million USD | 1.1% |
| 2003 Q2 | 1.82 Million USD | 5.88% |
| 2002 Q4 | 1.7 Million USD | -6.98% |
| 2002 Q1 | 1.72 Million USD | -3.23% |
| 2002 FY | 7.11 Million USD | -6.3% |
| 2002 Q2 | 1.85 Million USD | 7.2% |
| 2002 Q3 | 1.83 Million USD | -1.01% |
| 2001 Q4 | 1.78 Million USD | -0.7% |
| 2001 Q3 | 1.79 Million USD | -9.36% |
| 2001 FY | 7.59 Million USD | -3.84% |
| 2001 Q1 | 2.02 Million USD | 108.12% |
| 2001 Q2 | 1.98 Million USD | -2.31% |
| 2000 Q4 | 974.96 Thousand USD | -58.39% |
| 2000 Q2 | 2.37 Million USD | 7.69% |
| 2000 FY | 7.89 Million USD | -11.29% |
| 2000 Q1 | 2.2 Million USD | 0.17% |
| 2000 Q3 | 2.34 Million USD | -1.27% |
| 1999 Q1 | 2.2 Million USD | 0.0% |
| 1999 Q2 | 2.4 Million USD | 9.09% |
| 1999 Q3 | 2.1 Million USD | -12.5% |
| 1999 Q4 | 2.2 Million USD | 4.76% |
| 1999 FY | 8.9 Million USD | 12.66% |
| 1998 Q4 | 2.2 Million USD | 15.79% |
| 1998 Q1 | 1.7 Million USD | -5.56% |
| 1998 Q2 | 2.1 Million USD | 23.53% |
| 1998 FY | 7.9 Million USD | 12.86% |
| 1998 Q3 | 1.9 Million USD | -9.52% |
| 1997 Q1 | 1.4 Million USD | 0.0% |
| 1997 FY | 7 Million USD | 32.08% |
| 1997 Q2 | 2 Million USD | 42.86% |
| 1997 Q4 | 1.8 Million USD | 0.0% |
| 1997 Q3 | 1.8 Million USD | -10.0% |
| 1996 Q1 | 1.3 Million USD | 0.0% |
| 1996 FY | 5.3 Million USD | 12.77% |
| 1996 Q4 | 1.4 Million USD | 7.69% |
| 1996 Q3 | 1.3 Million USD | 0.0% |
| 1996 Q2 | 1.3 Million USD | 0.0% |
| 1995 Q2 | 1 Million USD | 0.0% |
| 1995 Q4 | 1.3 Million USD | 18.18% |
| 1995 Q3 | 1.1 Million USD | 10.0% |
| 1995 Q1 | 1 Million USD | 25.0% |
| 1995 FY | 4.7 Million USD | 30.56% |
| 1994 Q3 | 1 Million USD | 11.11% |
| 1994 Q4 | 800 Thousand USD | -20.0% |
| 1994 FY | 3.6 Million USD | 12.5% |
| 1994 Q2 | 900 Thousand USD | 12.5% |
| 1994 Q1 | 800 Thousand USD | 0.0% |
| 1993 Q1 | 800 Thousand USD | 117.78% |
| 1993 Q2 | 900 Thousand USD | 12.5% |
| 1993 Q3 | 700 Thousand USD | -22.22% |
| 1993 Q4 | 800 Thousand USD | 14.29% |
| 1993 FY | 3.2 Million USD | 10.34% |
| 1992 FY | 2.9 Million USD | 16.0% |
| 1992 Q3 | - USD | 0.0% |
| 1992 Q2 | - USD | -100.0% |
| 1992 Q1 | 800 Thousand USD | 120.51% |
| 1992 Q4 | -4.5 Million USD | 0.0% |
| 1991 FY | 2.5 Million USD | -10.71% |
| 1991 Q3 | - USD | 0.0% |
| 1991 Q4 | -3.9 Million USD | 0.0% |
| 1991 Q2 | - USD | -100.0% |
| 1991 Q1 | 600 Thousand USD | 115.79% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 FY | 2.8 Million USD | 2700.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q4 | -3.8 Million USD | 0.0% |
| 1989 Q2 | -1.2 Million USD | 0.0% |
| 1989 Q3 | - USD | 100.0% |
| 1989 FY | 100 Thousand USD | -94.44% |
| 1989 Q1 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 92.393% |
| Prenetics Global Limited | 60.73 Million USD | 81.339% |
| Star Equity Holdings, Inc. | 16.27 Million USD | 30.347% |
| CareDx, Inc | 277.76 Million USD | 95.92% |
| Exact Sciences Corporation | 2.06 Billion USD | 99.45% |
| Exagen Inc. | 52.29 Million USD | 78.326% |
| Inotiv, Inc. | 246.9 Million USD | 95.41% |
| Guardant Health, Inc. | 901.62 Million USD | 98.743% |
| Biodesix, Inc. | 77.41 Million USD | 85.36% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -188.905% |
| Precipio, Inc. | 13.63 Million USD | 16.894% |
| iSpecimen Inc. | 16.27 Million USD | 30.369% |
| Natera, Inc. | 938.98 Million USD | 98.793% |
| Aspira Women's Health Inc. | 24.11 Million USD | 52.998% |
| Standard BioTools Inc. | 113.48 Million USD | 90.013% |
| 23andMe Holding Co. | 420.73 Million USD | 97.306% |
| Castle Biosciences, Inc. | 242.78 Million USD | 95.332% |
| Personalis, Inc. | 128.14 Million USD | 91.155% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | 89.745% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | 31.254% |
| OpGen, Inc. | 30.65 Million USD | 63.031% |
| T2 Biosystems, Inc. | 41.49 Million USD | 72.685% |
| Myriad Genetics, Inc. | 600.1 Million USD | 98.111% |
| ICON Public Limited Company | 755.64 Million USD | 98.5% |
| NeoGenomics, Inc. | 341.25 Million USD | 96.679% |
| Star Equity Holdings, Inc. | 16.27 Million USD | 30.347% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 98.963% |
| RadNet, Inc. | 268.87 Million USD | 95.785% |
| MDxHealth SA | 71.25 Million USD | 84.094% |
| Illumina, Inc. | 3.81 Billion USD | 99.703% |
| Check-Cap Ltd. | 19.28 Million USD | 41.235% |
| Twist Bioscience Corporation | 354.18 Million USD | 96.8% |
| DarioHealth Corp. | 62.17 Million USD | 81.77% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 93.407% |
| Sera Prognostics, Inc. | 39.91 Million USD | 71.606% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -7.73% |
| OPKO Health, Inc. | 574.68 Million USD | 98.028% |
| Medpace Holdings, Inc. | 187.68 Million USD | 93.961% |
| Neogen Corporation | 405.23 Million USD | 97.203% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | 3.201% |
| Prenetics Global Limited | 60.73 Million USD | 81.339% |
| Mainz Biomed B.V. | 27.15 Million USD | 58.261% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -29.312% |
| Trinity Biotech plc | 46.49 Million USD | 75.623% |
| Neuronetics, Inc. | 82.25 Million USD | 86.222% |
| Sotera Health Company | 300.46 Million USD | 96.228% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -29.312% |